Mesalamine 4 Gm/60 ml/Budesonide 4 mg/60 ml Retention Enema is a specially compounded medication designed to treat a range of inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. This unique formulation combines the anti-inflammatory properties of mesalamine with the corticosteroid budesonide, creating a potent combination that effectively reduces inflammation and alleviates symptoms associated with these conditions.

The medication is contained in a ready-to-use liquid formulation in pre-filled enema bottles, designed for rectal administration. This delivery system allows for the medication to be retained in the rectum for an extended period, facilitating more effective absorption and improved therapeutic outcomes. This method provides a convenient, hygienic, and controlled application, eliminating the need for additional preparation.

This formulation is not only effective in treating ulcerative colitis and Crohn's disease, but it also provides relief from symptoms such as abdominal pain, diarrhea, and rectal bleeding. It is also beneficial in treating proctitis, a condition characterized by inflammation of the rectum. The combination of mesalamine and budesonide works synergistically to reduce inflammation and improve symptoms.

Patients should be aware that this formulation may cause side effects such as nausea, vomiting, and headache. It is also important to note that this medication may interact with other drugs. Therefore, it is crucial to discuss all medications and supplements with a healthcare provider before starting this treatment.

Healthcare providers should be aware that this formulation is a compounded medication and should be used with caution. Close monitoring of patients for any adverse reactions or interactions is essential to ensure safe and effective treatment.

If you have any questions about this formulation or its use in treating inflammatory bowel diseases, please do not hesitate to contact us. We are a team of experienced compounding pharmacists ready to assist you with your queries and concerns.

Mesalamine 4 Gm/60 ml/Budesonide 4 mg/60 ml Retention Enema is a compounded formulation designed for rectal administration. This combination medication is primarily used in the treatment of ulcerative colitis, proctitis, and proctosigmoiditis. It is specifically formulated to reduce inflammation and irritation in the rectum and colon, providing targeted relief for these conditions.

The formulation contains two active ingredients: Mesalamine and Budesonide. Both are corticosteroids that work by reducing inflammation in the rectum and colon. Mesalamine is an aminosalicylate, which further aids in reducing inflammation and irritation in the rectum and colon. Budesonide, on the other hand, is a corticosteroid that also helps to reduce inflammation and irritation in the rectum and colon.

It is crucial to note that this medication is not suitable for all patients. It should not be used by individuals with a known hypersensitivity to either mesalamine or budesonide. Additionally, it is not recommended for patients with severe liver or kidney disease, or for those who are pregnant or breastfeeding. Always consult with a healthcare provider before starting any new medication.

Patients are advised to take this medication as directed by their healthcare provider and to follow the instructions on the label carefully. It is not advisable to take more or less of this medication than prescribed. Misuse can lead to adverse effects or decreased effectiveness.

Like all medications, this formulation may cause side effects, including nausea, vomiting, diarrhea, abdominal pain, and headache. If these or any other side effects occur, patients should immediately contact their healthcare provider for advice.

If you have any questions or concerns about this formulation, please consult with your healthcare provider or pharmacist. They can provide you with the most accurate and up-to-date information based on your specific health situation.

Mesalamine 4 Gm/60 ml/Budesonide 4 mg/60 ml Retention Enema is a compounded formulation designed to treat ulcerative colitis, a type of inflammatory bowel disease. This formulation combines two potent medications: Mesalamine, an anti-inflammatory drug, and Budesonide, a corticosteroid. Both of these medications work synergistically to reduce inflammation and swelling in the colon, thereby alleviating symptoms such as abdominal pain, diarrhea, and rectal bleeding associated with ulcerative colitis.

This medication is administered as a retention enema, a ready-to-use liquid formulation contained in pre-filled enema bottles. The enema is inserted into the rectum and held there for approximately 15 minutes before being expelled. This method allows the medication to be absorbed directly into the lining of the colon, providing targeted treatment and ensuring maximum efficacy.

It is crucial to adhere to the instructions provided by your healthcare provider when using this medication. The enema should be administered at the same time each day to maintain a consistent level of medication in your system. It is also recommended to hold the enema in the rectum for the full 15 minutes before expulsion to ensure optimal absorption of the medication.

While using this medication, it is important to stay well-hydrated to prevent dehydration, a potential side effect of many medications. Always ensure you are drinking plenty of fluids throughout the day.

If you have any questions or concerns about using the Mesalamine 4 Gm/60 ml/Budesonide 4 mg/60 ml Retention Enema, do not hesitate to reach out to your healthcare provider or pharmacist. They can provide you with the necessary guidance and support to ensure you are using this medication safely and effectively.

This compounded formulation of Mesalamine 4 Gm/60 ml/Budesonide 4 mg/60 ml Retention Enema is a ready-to-use liquid solution, conveniently contained in pre-filled enema bottles for rectal administration. It is primarily utilized in the treatment of various gastrointestinal conditions such as Ulcerative Colitis, Crohn's Disease, Proctitis, Proctosigmoiditis, and Diverticulitis. The formulation may also be beneficial in managing other conditions like radiation proctitis, anal fissures, and fistulas, by reducing inflammation in the rectum and sigmoid colon.

Moreover, this formulation can be used as a preventive measure to reduce the risk of relapse in patients with ulcerative colitis who have achieved remission. However, it is crucial to understand that this formulation is not intended for the treatment of acute flares of ulcerative colitis or Crohn's disease. For any queries or concerns regarding the use of this formulation for any other condition, it is recommended to consult with a healthcare professional.